Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

8.010 -0.480 (-5.65%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,610,421
Open 8.500
Bid (Size) 8.040 (15)
Ask (Size) 8.070 (12)
Prev. Close 8.490
Today's Range 7.855 - 8.580
52wk Range 2.865 - 11.70
Shares Outstanding 67,578,549
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why CSL Ltd Stock Could Be Worth a Look
FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment. 
Via MarketBeat
Exposures Product Safety
Looking Into bluebird bio's Return On Capital Employed
 
Via Benzinga

Performance

YTD
-24.43%
-24.43%
1 Month
+30.67%
+30.67%
3 Month
+25.75%
+25.75%
6 Month
+168.79%
+168.79%
1 Year
-19.98%
-19.98%

More News

Read More
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
Via Benzinga
bluebird bio Sells Priority Review Voucher for $102 Million
From bluebird bio, Inc.
Via Business Wire
FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
Via Benzinga
Where Will Editas Medicine Be in 1 Year?
Via The Motley Fool
Analyst Ratings for bluebird bio
Via Benzinga
Recap: bluebird bio Q3 Earnings
Via Benzinga
2 Growth Stocks That Could Double in 2023
Via The Motley Fool
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
Via Benzinga
bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
Better Buy: CRISPR Therapeutics vs. Bluebird Bio
Via The Motley Fool
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Via Benzinga
Why Legend Biotech's Shares Jumped 14.2% On Tuesday
Via The Motley Fool
Biotech Stocks Well-Positioned For The Fourth Quarter
Via Talk Markets
Real Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy
From Real Endpoints
Via Globe NewsWire
Bluebird Bio Offers World's Most Expensive Drugs, But Uncertainty Looms Over Its Financial Future
Via Benzinga
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Via Benzinga
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday
Via Benzinga
US Stock Futures Mixed After Recording Losses Last Week; Fed Speakers In Focus
Via Benzinga
Amazon, bluebird bio And 3 Stocks To Watch Heading Into Monday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.